All News

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

Fighting cancer is hard, but fighting it when you have to bring your kids along for the ride makes it even harder.

Pinktober heralds the arrival of so much pink that some of us run screaming from the sight of it, despite the good intentions of Breast Cancer Awareness Month. As I explain how I have made my peace with pink, you might feel better about your own choices.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

A breast cancer patient's go-to resources for starting and continuing the cancer talk with your kids

Here are the top 5 CURE stories for September 2018.

Here are a few tips how to get the ball rolling on advocating for new legislation to help improve care.

The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

The line separating cancer and cancer-free isn't always thick and dark.

One problem for all of us cancer patients is just when we think we have learned our limits, they change.

Airbnb announced the expansion of its Open Homes platform, which offers free, temporary housing for patients and their families traveling for treatment or respite stays.

The FDA has approved the PD-1 inhibitor Libtayo (cemiplimab) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Individuals are willing to make great sacrifices to pay for their cancer treatment.

Diagnosing and treating the disease before it turns into AML is a key area of study, said Srdan Verstovsek, M.D., Ph.D., medical oncologist and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

Researchers discovered that at least 50 percent of people surveyed had an employment change because of their disease.

"The best way to predict your future is to create it." - Abraham Lincoln

The Food and Drug Administration (FDA) has approved Vizimpro (dacomitinib) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations, according to Pfizer, the manufacturer of the pan-human EGFR tyrosine kinase inhibitor (TKI).

Researchers determined that the use of methotrexate, vinblastine, doxorubicin and cisplatin before cystectomy may induce better outcomes for patients with advanced bladder cancer.

A recent study from St. Jude Children’s Hospital found that more than half of adults who survived pediatric central nervous system tumors failed to achieve independence as adults.

Cancer is scary, but the scares continue long after surgery and treatment are over. Learn some warning signs you should pay attention to in this article.

A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.

Although immunotherapy’s use in ovarian cancer lags other cancer types, Matthew Powell, M.D., believes there is still promise for checkpoint blockades in this field, likely in combination with other agents.

Getting a third opinion probably didn't save my life, but it definitely bought me more time.

Navigating the unknown is one of the hardest parts of living with cancer.

The IMpower133 trial demonstrated the added overall and progression-free survival benefits of adjuvant Tecentriq with standard of care therapy for patients with extensive-stage small cell lung cancer.

Don't let the excuse of cancer run your life or stop you from doing all that you want.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory and anxiety.

"Hugs" come in all kinds of forms.

Patient-caregiver communities focused on non-small cell lung cancer with genomic alterations offer support, awareness and education to help accelerate research in this space.